CA2856673C - Use of acetaminophen for reducing the frequency of urination - Google Patents

Use of acetaminophen for reducing the frequency of urination Download PDF

Info

Publication number
CA2856673C
CA2856673C CA2856673A CA2856673A CA2856673C CA 2856673 C CA2856673 C CA 2856673C CA 2856673 A CA2856673 A CA 2856673A CA 2856673 A CA2856673 A CA 2856673A CA 2856673 C CA2856673 C CA 2856673C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
release
acetaminophen
delayed
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2856673A
Other languages
English (en)
French (fr)
Other versions
CA2856673A1 (en
Inventor
David A. Dill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,349 external-priority patent/US20120141554A1/en
Priority claimed from US13/423,949 external-priority patent/US8236856B2/en
Priority claimed from US13/487,343 external-priority patent/US20120237574A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of CA2856673A1 publication Critical patent/CA2856673A1/en
Application granted granted Critical
Publication of CA2856673C publication Critical patent/CA2856673C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2856673A 2012-01-04 2012-08-22 Use of acetaminophen for reducing the frequency of urination Expired - Fee Related CA2856673C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/343,349 2012-01-04
US13/343,349 US20120141554A1 (en) 2010-07-08 2012-01-04 Delayed release formulation for reducing the frequency of urination and method of use thereof
US13/423,949 US8236856B2 (en) 2010-07-08 2012-03-19 Delayed release formulation for reducing the frequency of urination and method of use thereof
US13/423,949 2012-03-19
US13/487,343 US20120237574A1 (en) 2010-07-08 2012-06-04 Delayed-release formulation for reducing the frequency of urination and method of use thereof
US13/487,343 2012-06-04
PCT/US2012/051859 WO2013103389A1 (en) 2012-01-04 2012-08-22 Delayed-release formulation for reducing the frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
CA2856673A1 CA2856673A1 (en) 2013-07-11
CA2856673C true CA2856673C (en) 2018-08-21

Family

ID=48745354

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2856673A Expired - Fee Related CA2856673C (en) 2012-01-04 2012-08-22 Use of acetaminophen for reducing the frequency of urination

Country Status (12)

Country Link
US (2) US8703184B2 (enExample)
JP (3) JP2015506359A (enExample)
KR (3) KR20190049928A (enExample)
AU (1) AU2012363788B2 (enExample)
BR (1) BR112014016550A8 (enExample)
CA (1) CA2856673C (enExample)
IL (1) IL232711A0 (enExample)
MX (1) MX2014008284A (enExample)
RU (1) RU2597156C2 (enExample)
SG (1) SG11201500410XA (enExample)
WO (1) WO2013103389A1 (enExample)
ZA (1) ZA201403762B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105330B2 (en) * 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) * 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
WO2016041036A1 (pt) * 2014-09-19 2016-03-24 Diffucap Chemobras Química E Farmacéutical Ltda Combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
WO2017039832A1 (en) * 2015-09-01 2017-03-09 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
HK1259196A1 (zh) * 2015-09-01 2019-11-29 韦尔斯利医药有限公司 延迟释放制剂、其制备方法和用途
KR102314838B1 (ko) 2021-04-01 2021-10-19 송관권 터널 비개착공법
KR102364887B1 (ko) 2021-06-14 2022-02-18 송관권 터널 비개착 일체식 압입공법 및 그에 적용되는 일체식 가설구조물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207940B (en) * 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
ATE169498T1 (de) * 1991-09-06 1998-08-15 Mcneilab Inc Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
DE69830728T2 (de) * 1997-04-11 2006-05-18 Nippon Shinyaku Co., Ltd. Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
CN1296417A (zh) * 1998-02-10 2001-05-23 卫福有限公司 控释制剂
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
AU7360700A (en) 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
EP1313478A2 (en) 2000-08-30 2003-05-28 Lilly Icos LLC Method for treatment of migraine using pde5 inhibitors
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
WO2003029199A1 (en) 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Benzene derivatives, process for preparing the same and use thereof
EP1447096A1 (en) * 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
JP2005526040A (ja) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用
PL374646A1 (en) * 2002-07-08 2005-10-31 Pliva-Istrazivacki Institutt D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
EP1535922A4 (en) 2002-07-11 2006-10-04 Takeda Pharmaceutical PYRROLOPYRIDINE DERIVATIVE AND ITS USE
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
WO2007083323A2 (en) 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
US20090069275A1 (en) 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
EP2068837A2 (en) 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
WO2008021625A2 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
CA2695634C (en) 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
MX2014008284A (es) 2015-03-03
KR20140108674A (ko) 2014-09-12
AU2012363788B2 (en) 2017-03-09
JP2015506359A (ja) 2015-03-02
BR112014016550A8 (pt) 2017-07-04
WO2013103389A1 (en) 2013-07-11
AU2012363788A2 (en) 2014-07-24
US20140154314A1 (en) 2014-06-05
US8703184B2 (en) 2014-04-22
NZ626622A (en) 2016-11-25
RU2014131238A (ru) 2016-02-20
KR20180023057A (ko) 2018-03-06
KR20190049928A (ko) 2019-05-09
ZA201403762B (en) 2015-10-28
JP2017122091A (ja) 2017-07-13
RU2597156C2 (ru) 2016-09-10
JP2019055969A (ja) 2019-04-11
SG11201500410XA (en) 2015-04-29
BR112014016550A2 (pt) 2017-06-13
CA2856673A1 (en) 2013-07-11
IL232711A0 (en) 2014-07-31
AU2012363788A1 (en) 2014-07-17
US20130224291A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
CA2856673C (en) Use of acetaminophen for reducing the frequency of urination
US20120141554A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
AU2017203418B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120135050A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8445015B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
HK1249438A1 (zh) 用於缓解尿频的缓释制剂及其使用方法
US8445011B2 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
AU2016317092A1 (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) Delayed-release formulations, methods of making and use thereof
EP2612662B1 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
EP2612661B1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
TWI590822B (zh) 用於減少排尿頻率的延遲釋放製劑及其使用方法
AU2016317093A1 (en) Delayed-release formulations, methods of making and use thereof
NZ626622B2 (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
WO2013103356A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150826

MKLA Lapsed

Effective date: 20200831